InSphero Year in Review, Cross-species Hepatotoxicity Testing, LDH Assay Technical Protocol, Melanie Aregger Promoted to COO

Dear Manu
 
As the holiday season fast approaches and 2015 draws to a close, we want to thank you for your continued interest in InSphero 3D microtissues and services. We value your suggestions and are eager to hear more about how you’ve applied 3D microtissues in your work — and learn which microtissues and services are on your 2016 wish list! Click here to send us a note and tell us what you want!  

We hope you enjoy this month's newsletter, in which we feature our 2015 Year in Review, put a bow on our new Cross-species Hepatotoxicity Testing Service, unwrap a new technical protocol, and more.  

Holiday Hours:  InSphero will be closed for the holidays from noon on December 23, 2015 through January 3, 2016. Happy Holidays from our team to yours!
InSide
 
2015:  A Year of Innovation and Growth at InSphero
 
The holidays are a time of reflection and celebration.  We invite you to take a visual tour of some highlights from 2015 at InSphero, from patent approval for our GravityPLUSâ„¢ Hanging Drop System and the introduction of our GravityTRAPâ„¢ ULA Plate to new microtissues, toxicology screening services, and spheroid imaging technologies — all designed to help you get the most meaningful results from your investment in
3D model systems.
 

 
InFocus
3D InSightâ„¢ Cross-species Hepatotoxicity Testing
 
Cross-species Hepatotoxicity Testing is a great way to prioritize your compounds of interest before investing in costly animal studies!  This convenient service assesses hepatotoxicity (via ATP assay) over 7 days with repeat dosing in any three of our 3D InSightâ„¢ Human, Rat, Dog, Cynomolgus, or Minipig Microtissues.  Standard packages for 5, 10, or 20 compounds available.  
 
InPress

New Technical Protocol:  LDH Assay for Assessing Microtissue Health
 
Did you know InSphero provides 3D-optimized technical protocols to help you achieve the best results and collect clean, relevant experimental data when you’re using our assay-ready microtissues? Our newest protocol assesses microtissue health by measuring LDH release as an endpoint for cell viability using the Promega CytoTox-ONEâ„¢ assay. 
 

 
 
Let us know if you have a favorite assay you’d like to see optimized for use with
3D microtissues.  
InSide

Melanie Aregger Promoted to COO
 
Congratulations to InSphero Management Team Member and Head of InSphero Diagnostics Melanie Aregger on her recent promotion to Chief Operating Officer!  Aregger, who received the Megatrend Health 2015 Women’s Business award for her achievements while at InSphero, will assume responsibility for managing InSphero operations, purchasing and bioproduction functions, while continuing to direct our Diagnostics divison.
 
Facebook
Facebook
Twitter
Twitter
Website
Website
Copyright © 2015 InSphero, All rights reserved.


unsubscribe from this list    update subscription preferences